Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.
First Listening Session Held at USCA to Inform Updates to National HIV/AIDS Strategy and National Viral Hepatitis Action Plans
The U.S. Department of Health and Human Services was at USCA 2018 to hear from community members about their ideas on priorities and issues to be addressed in updates to the National HIV/AIDS Strategy and National Viral Hepatitis Action Plan, both of...
On the third day of the 2018 U.S. Conference on AIDS (USCA) Corinna Dan, R.N., M.P.H., viral hepatitis policy advisor at HHS's Office of HIV/AIDS and Infectious Disease Policy, shared information from her conference presentation.
A combination of glecaprevir and pibrentasvir (Mavyret), has been approved for hepatitis C treatment, for any genotype, with a treatment duration of only eight weeks -- four weeks less than most other current regimens.
"Vosevi provides a treatment option for some patients who were not successfully treated with other HCV drugs in the past."
The U.S. Food and Drug Administration has approved Epclusa (sofosbuvir/velpatasvir) to treat adult patients with chronic hepatitis C virus. It is the first to treat all six major forms of HCV.
Who has the power to prescribe medications? In the ongoing struggle to cure the estimated 3.2 million people living with chronic hepatitis C virus (HCV) infection in the U.S., the answer may not be who you think.
On Jan. 9, the U.S. Food and Drug Administration (FDA) approved a three-in-one test that detects HIV, hepatitis C and hepatitis B.
The U.S. Food and Drug Administration approved yet another hepatitis C treatment option on Dec. 19. The new combination, called Viekira Pak, may create the first major competition for Harvoni, which was approved earlier this year.
The Fair Pricing Coalition, a U.S. treatment activist organisation, called for Gilead to set a single uniform per-cure price for the coformulation of sofosbuvir and ledipasvir (brand name Harvoni) irrespective of whether 8, 12, or 24 weeks of treatme...